首页 > 最新文献

Critical Care and Resuscitation最新文献

英文 中文
Management of severe acute respiratory distress syndrome in Australia and New Zealand (SAGE-ANZ): An observational study 澳大利亚和新西兰严重急性呼吸窘迫综合征的管理(SAGE-ANZ):观察研究
IF 1.4 4区 医学 Q3 CRITICAL CARE MEDICINE Pub Date : 2024-09-01 Epub Date: 2024-06-21 DOI: 10.1016/j.ccrj.2024.05.001
Rachael L. Parke RN, PhD , Shay P. McGuinness MBChB , Alana Cavadino PhD , Keri-Anne Cowdrey RN, MN , Samantha Bates RN, MN , Shailesh Bihari MBBS, PhD , Amanda Corley RN, PhD , Eileen Gilder RN, PhD , Carol Hodgson PhD , Edward Litton MBChB, PhD , Colin McArthur MBChB , Alistair Nichol MBBCh, PhD , Jane Parker RN, MPH , Anne Turner RN, MPH , Steve Webb MBBS, PhD , Frank MP. Van Haren MD, PhD , SAGE-ANZ Study Investigators and the Australia and New Zealand Intensive Care Society Clinical Trials Group

Objective

Acute respiratory distress syndrome (ARDS) is associated with significant mortality, morbidity, and cost. We aimed to describe characteristics and management of adult patients admitted to intensive care units (ICUs) in Australia and New Zealand with moderate-severe ARDS, to better understand contemporary practice.

Design

Bi-national, prospective, observational, multi-centre study.

Setting

19 ICUs in Australia and New Zealand.

Participants

Mechanically ventilated patients with moderate-severe ARDS.

Main outcome measures

Baseline demographic characteristics, ventilation characteristics, use of adjunctive support therapy and all-cause mortality to day 28. Data were summarised using descriptive statistics.

Results

200 participants were enrolled, mean (±SD) age 55.5 (±15.9) years, 40% (n = 80) female. Around half (51.5%) had no baseline comorbidities and 45 (31%) tested positive for COVID-19. On day 1, mean SOFA score was 9 ± 3; median (IQR) PaO2/FiO2 ratio 119 (89, 142), median (IQR) FiO2 70% (50%, 99%) and mean (±SD) positive end expiratory pressure (PEEP) 11 (±3) cmH2O. On day one, 10.5% (n = 21) received lung protective ventilation (LPV) (tidal volume ≤6.5 mL/kg predicted body weight and plateau pressure or peak pressure ≤30 cm H2O). Adjunctive therapies were received by 86% (n = 172) of patients at some stage from enrolment to day 28. Systemic steroids were most used (n = 127) followed by neuromuscular blockers (n = 122) and prone positioning (n = 27). Median ventilator-free days (IQR) to day 28 was 5 (0, 20). In-hospital mortality, censored at day 28, was 30.5% (n = 61).

Conclusions

In Australia and New Zealand, compliance with evidence-based practices including LPV and prone positioning was low in this cohort. Therapies with proven benefit in the treatment of patients with moderate-severe ARDS, such as lung protective ventilation and prone positioning, were not routinely employed.

目的急性呼吸窘迫综合征(ARDS)与严重的死亡率、发病率和成本相关。我们旨在描述澳大利亚和新西兰重症监护病房(ICU)收治的中重度ARDS成人患者的特征和管理情况,以便更好地了解当代的实践。结果200名参与者,平均(±SD)年龄为55.5(±15.9)岁,40%(n = 80)为女性。约半数(51.5%)患者无基线合并症,45人(31%)COVID-19检测呈阳性。第一天,平均 SOFA 评分为 9 ± 3;PaO2/FiO2 比率中位数(IQR)为 119(89,142),FiO2 中位数(IQR)为 70%(50%,99%),呼气末正压(PEEP)平均值(±SD)为 11(±3)cmH2O。第一天,10.5%(n = 21)的患者接受了肺保护性通气(LPV)(潮气量≤6.5 mL/kg预测体重,高原压或峰值压≤30 cm H2O)。86%的患者(n = 172)在入组至第 28 天的某个阶段接受了辅助治疗。使用最多的是全身类固醇(127 人),其次是神经肌肉阻滞剂(122 人)和俯卧位(27 人)。截至第28天的无呼吸机天数中位数(IQR)为5天(0,20)。结论在澳大利亚和新西兰,包括 LPV 和俯卧位在内的循证疗法在该队列中的依从性很低。在澳大利亚和新西兰,包括 LPV 和俯卧位在内的循证实践的依从性较低。在中度重度 ARDS 患者的治疗中,肺保护性通气和俯卧位等已证实有效的疗法并未得到常规采用。
{"title":"Management of severe acute respiratory distress syndrome in Australia and New Zealand (SAGE-ANZ): An observational study","authors":"Rachael L. Parke RN, PhD ,&nbsp;Shay P. McGuinness MBChB ,&nbsp;Alana Cavadino PhD ,&nbsp;Keri-Anne Cowdrey RN, MN ,&nbsp;Samantha Bates RN, MN ,&nbsp;Shailesh Bihari MBBS, PhD ,&nbsp;Amanda Corley RN, PhD ,&nbsp;Eileen Gilder RN, PhD ,&nbsp;Carol Hodgson PhD ,&nbsp;Edward Litton MBChB, PhD ,&nbsp;Colin McArthur MBChB ,&nbsp;Alistair Nichol MBBCh, PhD ,&nbsp;Jane Parker RN, MPH ,&nbsp;Anne Turner RN, MPH ,&nbsp;Steve Webb MBBS, PhD ,&nbsp;Frank MP. Van Haren MD, PhD ,&nbsp;SAGE-ANZ Study Investigators and the Australia and New Zealand Intensive Care Society Clinical Trials Group","doi":"10.1016/j.ccrj.2024.05.001","DOIUrl":"10.1016/j.ccrj.2024.05.001","url":null,"abstract":"<div><h3>Objective</h3><p>Acute respiratory distress syndrome (ARDS) is associated with significant mortality, morbidity, and cost. We aimed to describe characteristics and management of adult patients admitted to intensive care units (ICUs) in Australia and New Zealand with moderate-severe ARDS, to better understand contemporary practice.</p></div><div><h3>Design</h3><p>Bi-national, prospective, observational, multi-centre study.</p></div><div><h3>Setting</h3><p>19 ICUs in Australia and New Zealand.</p></div><div><h3>Participants</h3><p>Mechanically ventilated patients with moderate-severe ARDS.</p></div><div><h3>Main outcome measures</h3><p>Baseline demographic characteristics, ventilation characteristics, use of adjunctive support therapy and all-cause mortality to day 28. Data were summarised using descriptive statistics.</p></div><div><h3>Results</h3><p>200 participants were enrolled, mean (±SD) age 55.5 (±15.9) years, 40% (n = 80) female. Around half (51.5%) had no baseline comorbidities and 45 (31%) tested positive for COVID-19. On day 1, mean SOFA score was 9 ± 3; median (IQR) PaO<sub>2</sub>/FiO<sub>2</sub> ratio 119 (89, 142), median (IQR) FiO<sub>2</sub> 70% (50%, 99%) and mean (±SD) positive end expiratory pressure (PEEP) 11 (±3) cmH<sub>2</sub>O. On day one, 10.5% (n = 21) received lung protective ventilation (LPV) (tidal volume ≤6.5 mL/kg predicted body weight and plateau pressure or peak pressure ≤30 cm H<sub>2</sub>O). Adjunctive therapies were received by 86% (n = 172) of patients at some stage from enrolment to day 28. Systemic steroids were most used (n = 127) followed by neuromuscular blockers (n = 122) and prone positioning (n = 27). Median ventilator-free days (IQR) to day 28 was 5 (0, 20). In-hospital mortality, censored at day 28, was 30.5% (n = 61).</p></div><div><h3>Conclusions</h3><p>In Australia and New Zealand, compliance with evidence-based practices including LPV and prone positioning was low in this cohort. Therapies with proven benefit in the treatment of patients with moderate-severe ARDS, such as lung protective ventilation and prone positioning, were not routinely employed.</p></div>","PeriodicalId":49215,"journal":{"name":"Critical Care and Resuscitation","volume":"26 3","pages":"Pages 161-168"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1441277224000139/pdfft?md5=d534b9440be94c4ac8edd575b084a64d&pid=1-s2.0-S1441277224000139-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142230330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brain tissue oxygen monitoring in moderate-to-severe traumatic brain injury: Physiological determinants, clinical interventions and current randomised controlled trial evidence 中重度创伤性脑损伤的脑组织氧监测:生理决定因素、临床干预措施和当前随机对照试验证据
IF 1.4 4区 医学 Q3 CRITICAL CARE MEDICINE Pub Date : 2024-09-01 Epub Date: 2024-06-27 DOI: 10.1016/j.ccrj.2024.05.003
Toby Jeffcote FCICM, PhD , Kuan-Ying Lu MBiomedEng , Philip Lewis PhD , Dashiell Gantner FCICM, PhD , Camila R. Battistuzzo PhD , Andrew A. Udy FCICM, PhD

Modern intensive care for moderate-to-severe traumatic brain injury (msTBI) focuses on managing intracranial pressure (ICP) and cerebral perfusion pressure (CPP). This approach lacks robust clinical evidence and often overlooks the impact of hypoxic injuries. Emerging monitoring modalities, particularly those capable of measuring brain tissue oxygen, represent a promising avenue for advanced neuromonitoring. Among these, brain tissue oxygen tension (PbtO2) shows the most promising results. However, there is still a lack of consensus regarding the interpretation of PbtO2 in clinical practice. This review aims to provide an overview of the pathophysiological rationales, monitoring technology, physiological determinants, and recent clinical trial evidence for PbtO2 monitoring in the management of msTBI.

中重度创伤性脑损伤(msTBI)的现代重症监护主要集中在颅内压(ICP)和脑灌注压(CPP)的管理上。这种方法缺乏可靠的临床证据,而且经常忽视缺氧性损伤的影响。新出现的监测模式,尤其是那些能够测量脑组织氧的监测模式,为先进的神经监测带来了希望。其中,脑组织氧张力(PbtO2)显示出最有希望的结果。然而,临床实践中对 PbtO2 的解释仍缺乏共识。本综述旨在概述病理生理学原理、监测技术、生理决定因素,以及在毫秒创伤性脑损伤治疗中进行 PbtO2 监测的最新临床试验证据。
{"title":"Brain tissue oxygen monitoring in moderate-to-severe traumatic brain injury: Physiological determinants, clinical interventions and current randomised controlled trial evidence","authors":"Toby Jeffcote FCICM, PhD ,&nbsp;Kuan-Ying Lu MBiomedEng ,&nbsp;Philip Lewis PhD ,&nbsp;Dashiell Gantner FCICM, PhD ,&nbsp;Camila R. Battistuzzo PhD ,&nbsp;Andrew A. Udy FCICM, PhD","doi":"10.1016/j.ccrj.2024.05.003","DOIUrl":"10.1016/j.ccrj.2024.05.003","url":null,"abstract":"<div><p>Modern intensive care for moderate-to-severe traumatic brain injury (msTBI) focuses on managing intracranial pressure (ICP) and cerebral perfusion pressure (CPP). This approach lacks robust clinical evidence and often overlooks the impact of hypoxic injuries. Emerging monitoring modalities, particularly those capable of measuring brain tissue oxygen, represent a promising avenue for advanced neuromonitoring. Among these, brain tissue oxygen tension (PbtO<sub>2</sub>) shows the most promising results. However, there is still a lack of consensus regarding the interpretation of PbtO<sub>2</sub> in clinical practice. This review aims to provide an overview of the pathophysiological rationales, monitoring technology, physiological determinants, and recent clinical trial evidence for PbtO<sub>2</sub> monitoring in the management of msTBI.</p></div>","PeriodicalId":49215,"journal":{"name":"Critical Care and Resuscitation","volume":"26 3","pages":"Pages 204-209"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1441277224000152/pdfft?md5=e58a24cff9d40d7de6e006570777fc6b&pid=1-s2.0-S1441277224000152-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142230443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A retrospective registry-based study into the proportion of patients admitted to intensive care who have anaphylaxis as a principal diagnosis and their outcomes in Australia and New Zealand 基于登记簿的回顾性研究:澳大利亚和新西兰重症监护病房收治的主要诊断为过敏性休克的患者比例及其治疗结果
IF 1.4 4区 医学 Q3 CRITICAL CARE MEDICINE Pub Date : 2024-09-01 Epub Date: 2024-08-03 DOI: 10.1016/j.ccrj.2024.06.002
Zheng Jie Lim (Zee) MBBS (Hons), MMed Periop , Dharshi Karalapillai MBBS, PhD, FANZCA, FCICM, PGDipUS , Helen Kolawole BMedSc, MBBS, MClinEd, FANZCA , Chris Fiddes MBBS, FANZCA , David Pilcher MBBS, MRCP, FRACP, FCICM , Ashwin Subramaniam MBBS, MMed, GChPOM, FRACP, FCICM, PhD

Objective

To describe the proportion of patients admitted to intensive care who have anaphylaxis as a principal diagnosis and their subsequent outcomes in Australia and New Zealand.

Design

Retrospective observational study of ICU admissions for severe anaphylaxis.

Setting

ICU admissions recorded in the Australian and New Zealand Intensive Care Society Adult Patient Database between 2012 and 2022.

Participants

Adults 16 years or older with severe anaphylaxis admitted to the ICU.

Interventions

None.

Main outcome measures

Proportion of patients admitted to ICU who have anaphylaxis as a principal diagnosis, mortality rate, ICU and hospital length of stay.

Results

7189 of the 7270 ICU admissions for severe anaphylaxis recorded between 2012 and 2022, were included in the analysis. This represented a proportion from 0.25% in 2012 to 0.43% in 2022. ICU and hospital mortality were 0.4% and 0.8%, respectively. The proportion of ICUs reporting at least one severe anaphylaxis each year increased from 61.7% in 2012 to 83.0% in 2022. Most of the patients were discharged home (92.6%, n = 6660). Increasing age (OR = 1.055; 95%CI: 1.008–1.105) and SOFA scores (OR = 1.616; 95%CI: 1.265–2.065), an immunosuppressive chronic condition (OR = 16.572; 95%CI: 3.006–91.349) and an increasing respiratory rate above 16 breaths/min (OR = 1.116; 95%CI: 1.057–1.178) predicted in-hospital mortality in patients with anaphylaxis, while higher GCS decreased in-hospital mortality (OR = 0.827; 95%CI: 0.705–0.969).

Conclusions

The overall proportion of patients admitted to ICU who have anaphylaxis as a principal diagnosis has increased. In-hospital mortality remains low despite the need for vital organ support. Further studies should investigate these identified factors that may predict in-hospital mortality among these patients.

Trial registration

Not applicable.

目的描述澳大利亚和新西兰重症监护病房收治的主要诊断为过敏性休克的患者比例及其随后的预后.设计对重症监护病房收治的严重过敏性休克患者进行回顾性观察研究.设置2012年至2022年期间澳大利亚和新西兰重症监护协会成人患者数据库中记录的重症监护病房收治患者.干预措施无.主要结果测量重症监护病房收治的主要诊断为过敏性休克的患者比例.干预措施无。主要结果测量以过敏性休克为主要诊断的ICU入院患者比例、死亡率、ICU和住院时间。结果在2012年至2022年期间记录的7270例ICU严重过敏性休克入院患者中,有7189例被纳入分析。这一比例从2012年的0.25%上升到2022年的0.43%。重症监护病房和医院的死亡率分别为 0.4% 和 0.8%。每年至少报告一次严重过敏性休克的重症监护室比例从2012年的61.7%增至2022年的83.0%。大多数患者出院回家(92.6%,n = 6660)。年龄增加(OR = 1.055;95%CI:1.008-1.105)、SOFA 评分增加(OR = 1.616;95%CI:1.265-2.065)、免疫抑制性慢性疾病(OR = 16.572;95%CI:3.006-91.349)和呼吸频率超过 16 次/分(OR = 1.116;95%CI:1.057-1.178)预示着住院患者的过敏性休克发生率增加。结论ICU收治的以过敏性休克为主要诊断的患者总比例有所增加。尽管需要重要器官支持,但院内死亡率仍然很低。进一步的研究应调查这些已确定的可能预测这些患者院内死亡率的因素。
{"title":"A retrospective registry-based study into the proportion of patients admitted to intensive care who have anaphylaxis as a principal diagnosis and their outcomes in Australia and New Zealand","authors":"Zheng Jie Lim (Zee) MBBS (Hons), MMed Periop ,&nbsp;Dharshi Karalapillai MBBS, PhD, FANZCA, FCICM, PGDipUS ,&nbsp;Helen Kolawole BMedSc, MBBS, MClinEd, FANZCA ,&nbsp;Chris Fiddes MBBS, FANZCA ,&nbsp;David Pilcher MBBS, MRCP, FRACP, FCICM ,&nbsp;Ashwin Subramaniam MBBS, MMed, GChPOM, FRACP, FCICM, PhD","doi":"10.1016/j.ccrj.2024.06.002","DOIUrl":"10.1016/j.ccrj.2024.06.002","url":null,"abstract":"<div><h3>Objective</h3><p>To describe the proportion of patients admitted to intensive care who have anaphylaxis as a principal diagnosis and their subsequent outcomes in Australia and New Zealand.</p></div><div><h3>Design</h3><p>Retrospective observational study of ICU admissions for severe anaphylaxis.</p></div><div><h3>Setting</h3><p>ICU admissions recorded in the Australian and New Zealand Intensive Care Society Adult Patient Database between 2012 and 2022.</p></div><div><h3>Participants</h3><p>Adults 16 years or older with severe anaphylaxis admitted to the ICU.</p></div><div><h3>Interventions</h3><p>None.</p></div><div><h3>Main outcome measures</h3><p>Proportion of patients admitted to ICU who have anaphylaxis as a principal diagnosis, mortality rate, ICU and hospital length of stay.</p></div><div><h3>Results</h3><p>7189 of the 7270 ICU admissions for severe anaphylaxis recorded between 2012 and 2022, were included in the analysis. This represented a proportion from 0.25% in 2012 to 0.43% in 2022. ICU and hospital mortality were 0.4% and 0.8%, respectively. The proportion of ICUs reporting at least one severe anaphylaxis each year increased from 61.7% in 2012 to 83.0% in 2022. Most of the patients were discharged home (92.6%, n = 6660). Increasing age (OR = 1.055; 95%CI: 1.008–1.105) and SOFA scores (OR = 1.616; 95%CI: 1.265–2.065), an immunosuppressive chronic condition (OR = 16.572; 95%CI: 3.006–91.349) and an increasing respiratory rate above 16 breaths/min (OR = 1.116; 95%CI: 1.057–1.178) predicted in-hospital mortality in patients with anaphylaxis, while higher GCS decreased in-hospital mortality (OR = 0.827; 95%CI: 0.705–0.969).</p></div><div><h3>Conclusions</h3><p>The overall proportion of patients admitted to ICU who have anaphylaxis as a principal diagnosis has increased. In-hospital mortality remains low despite the need for vital organ support. Further studies should investigate these identified factors that may predict in-hospital mortality among these patients.</p></div><div><h3>Trial registration</h3><p>Not applicable.</p></div>","PeriodicalId":49215,"journal":{"name":"Critical Care and Resuscitation","volume":"26 3","pages":"Pages 185-191"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1441277224000176/pdfft?md5=f3d17dbf6c2d76f42f55e0c44acee7cb&pid=1-s2.0-S1441277224000176-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142230347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ARDS, guidelines and ANZ practice: The persistent disconnect ARDS、指南和澳新实践:长期脱节
IF 1.4 4区 医学 Q3 CRITICAL CARE MEDICINE Pub Date : 2024-09-01 Epub Date: 2024-09-10 DOI: 10.1016/j.ccrj.2024.08.005
Ary Serpa Neto MD, MSc, PhD
{"title":"ARDS, guidelines and ANZ practice: The persistent disconnect","authors":"Ary Serpa Neto MD, MSc, PhD","doi":"10.1016/j.ccrj.2024.08.005","DOIUrl":"10.1016/j.ccrj.2024.08.005","url":null,"abstract":"","PeriodicalId":49215,"journal":{"name":"Critical Care and Resuscitation","volume":"26 3","pages":"Pages 159-160"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1441277224000322/pdfft?md5=4c206667cb8d6cc357879153406c2ecc&pid=1-s2.0-S1441277224000322-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142230329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
More than one pathway: ECMO training and credentialing 不止一条途径:ECMO 培训和资格认证
IF 1.4 4区 医学 Q3 CRITICAL CARE MEDICINE Pub Date : 2024-09-01 Epub Date: 2024-07-31 DOI: 10.1016/j.ccrj.2024.06.004
Michael Kouch M.D, Nitin Puri M.D, Emily Damuth M.D, Christopher Noel M.D, Jason Bartock M.D, Adam Green M.D
{"title":"More than one pathway: ECMO training and credentialing","authors":"Michael Kouch M.D,&nbsp;Nitin Puri M.D,&nbsp;Emily Damuth M.D,&nbsp;Christopher Noel M.D,&nbsp;Jason Bartock M.D,&nbsp;Adam Green M.D","doi":"10.1016/j.ccrj.2024.06.004","DOIUrl":"10.1016/j.ccrj.2024.06.004","url":null,"abstract":"","PeriodicalId":49215,"journal":{"name":"Critical Care and Resuscitation","volume":"26 3","pages":"Pages 217-218"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S144127722400019X/pdfft?md5=a864133d5162fcfea509a90639d0efe9&pid=1-s2.0-S144127722400019X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142230445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Point-of-care creatinine vs. central laboratory creatinine in the critically ill 重症患者的床旁肌酐与中心实验室肌酐对比
IF 1.4 4区 医学 Q3 CRITICAL CARE MEDICINE Pub Date : 2024-09-01 Epub Date: 2024-08-05 DOI: 10.1016/j.ccrj.2024.07.002
Kyle C. White FCICM, MPH , James McCullough FCICM, MMed , Kiran Shekar FCICM, PhD , Siva Senthuran FCICM, MBBS , Kevin B. Laupland FCICM, PhD , Goce Dimeski BSc Med Lab, PhD , Ary Serpa-Neto FCICM, PhD , Rinaldo Bellomo MD, PhD , Queensland Critical Care Research Network (QCRCN)

Objective

Frequent measurement of creatinine by point-of-care testing (POCT) may facilitate the earlier detection of acute kidney injury (AKI) in critically ill patients. However, no robust data exist to confirm its equivalence to central laboratory testing. We aimed to conduct a multicenter study to compare POCT with central laboratory creatinine (CrC) measurement.

Design

Retrospective observational study, using hospital electronic medical records. Obtained paired point-of-care creatinine (CrP) from arterial blood gas machines and CrC.

Setting

Four intensive care units in Queensland, Australia.

Participants

Critically ill patients, where greater than 50% of POCT contained creatinine.

Main outcome measures

Mean difference, bias, and limits of agreement between two methods, and biochemical confounders.

Results

We studied 79,767 paired measurements in 19,118 patients, with a median Acute Physiology and Chronic Health Evaluation 3 score of 51. The mean CrC was 115.5 μmol/L (standard deviation: 100.2) compared to a CrP mean of 115 μmol/L (standard deviation: 100.7) (Pearson coefficient of 0.99). The mean difference between CrP and CrC was 0.49 μmol/L with 95% limits of agreement of −27 μmol/L and +28 μmol/L. Several biochemical variables were independently associated with the difference between tests (e.g., pH, potassium, lactate, glucose, and bilirubin), but their impact was small.

Conclusion

In critically ill patients, measurement of creatinine by POCT yields clinically equivalent values to those obtained by central laboratory measurement and can be easily used for more frequent monitoring of kidney function in such patients. These findings open the door to the use of POCT for the earlier detection of acute kidney injury in critically ill patients.

目的通过床旁检测(POCT)频繁测量肌酐有助于更早地发现重症患者的急性肾损伤(AKI)。然而,目前还没有可靠的数据证实其与中心实验室检测具有等效性。我们旨在开展一项多中心研究,对 POCT 和中心实验室肌酐 (CrC) 测量进行比较。结果我们对 19118 名患者的 79767 次配对测量进行了研究,患者的急性生理学和慢性健康评估 3 中位数为 51 分。CrC 平均值为 115.5 μmol/L(标准偏差:100.2),而 CrP 平均值为 115 μmol/L(标准偏差:100.7)(皮尔逊系数为 0.99)。CrP 和 CrC 的平均值相差 0.49 μmol/L,95% 的一致性范围为 -27 μmol/L 和 +28μmol/L。一些生化变量(如 pH 值、钾、乳酸、葡萄糖和胆红素)与检测之间的差异有独立关联,但影响较小。这些发现为使用 POCT 更早发现危重病人的急性肾损伤打开了大门。
{"title":"Point-of-care creatinine vs. central laboratory creatinine in the critically ill","authors":"Kyle C. White FCICM, MPH ,&nbsp;James McCullough FCICM, MMed ,&nbsp;Kiran Shekar FCICM, PhD ,&nbsp;Siva Senthuran FCICM, MBBS ,&nbsp;Kevin B. Laupland FCICM, PhD ,&nbsp;Goce Dimeski BSc Med Lab, PhD ,&nbsp;Ary Serpa-Neto FCICM, PhD ,&nbsp;Rinaldo Bellomo MD, PhD ,&nbsp;Queensland Critical Care Research Network (QCRCN)","doi":"10.1016/j.ccrj.2024.07.002","DOIUrl":"10.1016/j.ccrj.2024.07.002","url":null,"abstract":"<div><h3>Objective</h3><p>Frequent measurement of creatinine by point-of-care testing (POCT) may facilitate the earlier detection of acute kidney injury (AKI) in critically ill patients. However, no robust data exist to confirm its equivalence to central laboratory testing. We aimed to conduct a multicenter study to compare POCT with central laboratory creatinine (CrC) measurement.</p></div><div><h3>Design</h3><p>Retrospective observational study, using hospital electronic medical records. Obtained paired point-of-care creatinine (CrP) from arterial blood gas machines and CrC.</p></div><div><h3>Setting</h3><p>Four intensive care units in Queensland, Australia.</p></div><div><h3>Participants</h3><p>Critically ill patients, where greater than 50% of POCT contained creatinine.</p></div><div><h3>Main outcome measures</h3><p>Mean difference, bias, and limits of agreement between two methods, and biochemical confounders.</p></div><div><h3>Results</h3><p>We studied 79,767 paired measurements in 19,118 patients, with a median Acute Physiology and Chronic Health Evaluation 3 score of 51. The mean CrC was 115.5 μmol/L (standard deviation: 100.2) compared to a CrP mean of 115 μmol/L (standard deviation: 100.7) (Pearson coefficient of 0.99). The mean difference between CrP and CrC was 0.49 μmol/L with 95% limits of agreement of −27 μmol/L and +28 μmol/L. Several biochemical variables were independently associated with the difference between tests (e.g., pH, potassium, lactate, glucose, and bilirubin), but their impact was small.</p></div><div><h3>Conclusion</h3><p>In critically ill patients, measurement of creatinine by POCT yields clinically equivalent values to those obtained by central laboratory measurement and can be easily used for more frequent monitoring of kidney function in such patients. These findings open the door to the use of POCT for the earlier detection of acute kidney injury in critically ill patients.</p></div>","PeriodicalId":49215,"journal":{"name":"Critical Care and Resuscitation","volume":"26 3","pages":"Pages 198-203"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1441277224000279/pdfft?md5=fe53682e5d2e5687b85d3ba807712d31&pid=1-s2.0-S1441277224000279-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142230446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The cost of coffee 咖啡的成本
IF 1.4 4区 医学 Q3 CRITICAL CARE MEDICINE Pub Date : 2024-09-01 Epub Date: 2024-07-31 DOI: 10.1016/j.ccrj.2024.06.005
Amelia Elizabeth Street
{"title":"The cost of coffee","authors":"Amelia Elizabeth Street","doi":"10.1016/j.ccrj.2024.06.005","DOIUrl":"10.1016/j.ccrj.2024.06.005","url":null,"abstract":"","PeriodicalId":49215,"journal":{"name":"Critical Care and Resuscitation","volume":"26 3","pages":"Page 220"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1441277224000218/pdfft?md5=ce44d934335dbe211fbfeb6b1a11cce2&pid=1-s2.0-S1441277224000218-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142230448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perspectives on healing: Therapy dog 治疗的视角治疗犬
IF 1.4 4区 医学 Q3 CRITICAL CARE MEDICINE Pub Date : 2024-09-01 Epub Date: 2024-07-31 DOI: 10.1016/j.ccrj.2024.06.006
Martina Zib
{"title":"Perspectives on healing: Therapy dog","authors":"Martina Zib","doi":"10.1016/j.ccrj.2024.06.006","DOIUrl":"10.1016/j.ccrj.2024.06.006","url":null,"abstract":"","PeriodicalId":49215,"journal":{"name":"Critical Care and Resuscitation","volume":"26 3","pages":"Page 221"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1441277224000231/pdfft?md5=3f78bae756ce83ee3336680a53ebb91e&pid=1-s2.0-S1441277224000231-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142230449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sonographic evaluation of intracranial hemodynamics and pressure after out-of-hospital cardiac arrest: An exploratory sub-study of the TAME trial 院外心脏骤停后颅内血液动力学和压力的超声评估:TAME试验的一项探索性子研究
IF 1.4 4区 医学 Q3 CRITICAL CARE MEDICINE Pub Date : 2024-09-01 Epub Date: 2024-06-27 DOI: 10.1016/j.ccrj.2024.06.001
Halvor Ø. Guldbrandsen MD , Peter Juhl-Olsen MD, PhD , Glenn M. Eastwood MD, PhD , Kasper L. Wethelund BMSc , Anders M. Grejs MD, PhD

Objective

Targeted mild hypercapnia is a potential neuroprotective therapy after cardiac arrest. In this exploratory observational study, we aimed to explore the effects of targeted mild hypercapnia on cerebral microvascular resistance assessed by middle cerebral artery pulsatility index (MCA PI) and intracranial pressure estimated by optic nerve sheath diameter (ONSD) in resuscitated out-of-hospital cardiac arrest (OHCA) patients.

Design, setting, participants and interventions

Comatose adults resuscitated from OHCA were randomly allocated to targeted mild hypercapnia (PaCO2 50–55 mmHg) or targeted normocapnia (PaCO2 35–45 mmHg) for 24 h in the TAME trial.

Main outcome measures

Using transcranial Doppler and transorbital ultrasound, we obtained MCA PI and ONSD at 4, 24, and 48 h after randomization. Ultrasound parameters were compared between groups using a linear mixed effects model.

Results

Twelve consecutive patients were included, with seven patients in the mild hypercapnia group. MCA PI decreased from 4 to 24 h (p = 0.019) and was lower over the first 24 h in patients allocated to targeted mild hypercapnia compared with targeted normocapnia (p = 0.047). ONSD did not differ between groups or over time.

Conclusion

Cerebral microvascular resistance assessed by MCA PI decreased over 24 h and was lower in OHCA patients treated with targeted mild hypercapnia compared with targeted normocapnia. Targeted mild hypercapnia did not exert substantial effect on intracranial pressure as estimated by ONSD.

目的有针对性的轻度高碳酸血症是心脏骤停后一种潜在的神经保护疗法。在这项探索性观察研究中,我们旨在探讨有针对性的轻度高碳酸血症对院外心脏骤停(OHCA)复苏患者大脑中动脉搏动指数(MCA PI)评估的脑微血管阻力和视神经鞘直径(ONSD)估测的颅内压的影响。设计、环境、参与者和干预措施在 TAME 试验中,院外心脏骤停(OHCA)复苏的成人患者被随机分配到目标性轻度高碳酸血症(PaCO2 50-55 mmHg)或目标性正常碳酸血症(PaCO2 35-45 mmHg)治疗 24 小时。主要结果测量通过经颅多普勒和经眶超声,我们在随机分配后的 4、24 和 48 小时获得了 MCA PI 和 ONSD。采用线性混合效应模型比较了不同组间的超声参数。从 4 小时到 24 小时,MCA PI 有所下降(p = 0.019),与正常碳酸血症组相比,轻度高碳酸血症组患者的 MCA PI 在前 24 小时内更低(p = 0.047)。结论 通过 MCA PI 评估的脑微血管阻力在 24 小时内有所下降,与正常碳酸血症相比,定向轻度高碳酸血症治疗的 OHCA 患者的脑微血管阻力更低。有针对性的轻度高碳酸血症并未对ONSD估测的颅内压产生实质性影响。
{"title":"Sonographic evaluation of intracranial hemodynamics and pressure after out-of-hospital cardiac arrest: An exploratory sub-study of the TAME trial","authors":"Halvor Ø. Guldbrandsen MD ,&nbsp;Peter Juhl-Olsen MD, PhD ,&nbsp;Glenn M. Eastwood MD, PhD ,&nbsp;Kasper L. Wethelund BMSc ,&nbsp;Anders M. Grejs MD, PhD","doi":"10.1016/j.ccrj.2024.06.001","DOIUrl":"10.1016/j.ccrj.2024.06.001","url":null,"abstract":"<div><h3>Objective</h3><p>Targeted mild hypercapnia is a potential neuroprotective therapy after cardiac arrest. In this exploratory observational study, we aimed to explore the effects of targeted mild hypercapnia on cerebral microvascular resistance assessed by middle cerebral artery pulsatility index (MCA PI) and intracranial pressure estimated by optic nerve sheath diameter (ONSD) in resuscitated out-of-hospital cardiac arrest (OHCA) patients.</p></div><div><h3>Design, setting, participants and interventions</h3><p>Comatose adults resuscitated from OHCA were randomly allocated to targeted mild hypercapnia (PaCO<sub>2</sub> 50–55 mmHg) or targeted normocapnia (PaCO<sub>2</sub> 35–45 mmHg) for 24 h in the TAME trial.</p></div><div><h3>Main outcome measures</h3><p>Using transcranial Doppler and transorbital ultrasound, we obtained MCA PI and ONSD at 4, 24, and 48 h after randomization. Ultrasound parameters were compared between groups using a linear mixed effects model.</p></div><div><h3>Results</h3><p>Twelve consecutive patients were included, with seven patients in the mild hypercapnia group. MCA PI decreased from 4 to 24 h (p = 0.019) and was lower over the first 24 h in patients allocated to targeted mild hypercapnia compared with targeted normocapnia (p = 0.047). ONSD did not differ between groups or over time.</p></div><div><h3>Conclusion</h3><p>Cerebral microvascular resistance assessed by MCA PI decreased over 24 h and was lower in OHCA patients treated with targeted mild hypercapnia compared with targeted normocapnia. Targeted mild hypercapnia did not exert substantial effect on intracranial pressure as estimated by ONSD.</p></div>","PeriodicalId":49215,"journal":{"name":"Critical Care and Resuscitation","volume":"26 3","pages":"Pages 176-184"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1441277224000164/pdfft?md5=f7af3cbe49d6aa5ac5495abd615c7474&pid=1-s2.0-S1441277224000164-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142230346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A multicentre point prevalence study of nocturnal hours awake and enteral pharmacological sleep aids in patients admitted to Australian and New Zealand intensive care units 关于澳大利亚和新西兰重症监护病房住院病人夜间清醒时间和肠道药物助眠的多中心点流行率研究
IF 1.4 4区 医学 Q3 CRITICAL CARE MEDICINE Pub Date : 2024-09-01 Epub Date: 2024-07-31 DOI: 10.1016/j.ccrj.2024.06.009
Laurie Showler MBChB , Adam M. Deane MBBS PhD , Edward Litton MBChB MSc , Melissa J. Ankravs BPharm MClinPharm , Bradley Wibrow MBBS MSc , Deborah Barge RN RM CCRN , Jeremy Goldin MBBS MM , Naomi Hammond RN MN PhD , Manoj K. Saxena MMBChir BSc , Paul J. Young MBChB PhD , Bala Venkatesh MBBS MD , Mark Finnis MBBS MBiostat , Yasmine Ali Abdelhamid MBBS PhD

Objective

Critically ill patients suffer disrupted sleep. Hypnotic medications may improve sleep; however, local epidemiological data regarding the amount of nocturnal time awake and the use of such medications is needed.

Design

Point prevalence study.

Setting

Adult ICUs in Australia and New Zealand.

Participants

All adult patients admitted to participating Intensive Care Units (ICUs) on the study day.

Main outcome measures

Time awake overnight (22:00–06:00) was determined by structured nurse observation. The use of enterally administered sedative-hypnotic drugs prior to and during ICU admission was recorded, as was the use of a unit policy and non-pharmacological sleep promotion strategies.

Results

Data were available for 532 patients admitted to 40 ICUs (median age 60 years, 336 (63.2%) male, and 222 (41.7%) invasively ventilated). Forty-eight patients (9.0%) received an enteral pharmacological sleep aid, of which melatonin (28, 5.2%) was most frequently used. Patients not invasively ventilated were observed to be awake overnight for a median of 4.0 h (interquartile range (IQR): 2.5, 5.5), with no difference in those receiving an enteral hypnotic (p = 0.9). Non-pharmacological sleep aids were reportedly not offered or available for 52% (earplugs) and 63% of patients (eye masks). Only 7 (17.5%) participating ICUs had a policy informing sleep-optimising interventions.

Conclusions

Patients not receiving invasive ventilation appeared to spend many nocturnal hours awake. Pharmacological sleep aid administration was not associated with a greater observed time asleep. Most patients did not receive any non-pharmacological aid, and most ICUs did not have a local guideline or unit policy on sleep promotion.

目标重症患者的睡眠受到干扰。催眠药物可能会改善睡眠;但是,我们需要有关夜间清醒时间和此类药物使用情况的本地流行病学数据。结果 40 个重症监护病房共收治了 532 名患者(中位年龄 60 岁,336 名(63.2%)男性,222 名(41.7%)有创通气患者)。48名患者(9.0%)接受了肠内药物助眠治疗,其中最常用的是褪黑素(28人,5.2%)。据观察,未接受有创通气的患者整夜清醒的时间中位数为 4.0 小时(四分位数间距 (IQR):2.5, 5.5),接受肠内催眠药的患者之间没有差异(p = 0.9)。据报道,52% 的患者(耳塞)和 63% 的患者(眼罩)没有或无法获得非药物睡眠辅助工具。只有 7 个(17.5%)参与研究的 ICU 制定了睡眠优化干预政策。药物助眠与睡眠时间延长无关。大多数患者没有接受任何非药物辅助治疗,大多数重症监护病房没有制定促进睡眠的地方指南或单位政策。
{"title":"A multicentre point prevalence study of nocturnal hours awake and enteral pharmacological sleep aids in patients admitted to Australian and New Zealand intensive care units","authors":"Laurie Showler MBChB ,&nbsp;Adam M. Deane MBBS PhD ,&nbsp;Edward Litton MBChB MSc ,&nbsp;Melissa J. Ankravs BPharm MClinPharm ,&nbsp;Bradley Wibrow MBBS MSc ,&nbsp;Deborah Barge RN RM CCRN ,&nbsp;Jeremy Goldin MBBS MM ,&nbsp;Naomi Hammond RN MN PhD ,&nbsp;Manoj K. Saxena MMBChir BSc ,&nbsp;Paul J. Young MBChB PhD ,&nbsp;Bala Venkatesh MBBS MD ,&nbsp;Mark Finnis MBBS MBiostat ,&nbsp;Yasmine Ali Abdelhamid MBBS PhD","doi":"10.1016/j.ccrj.2024.06.009","DOIUrl":"10.1016/j.ccrj.2024.06.009","url":null,"abstract":"<div><h3>Objective</h3><p>Critically ill patients suffer disrupted sleep. Hypnotic medications may improve sleep; however, local epidemiological data regarding the amount of nocturnal time awake and the use of such medications is needed.</p></div><div><h3>Design</h3><p>Point prevalence study.</p></div><div><h3>Setting</h3><p>Adult ICUs in Australia and New Zealand.</p></div><div><h3>Participants</h3><p>All adult patients admitted to participating Intensive Care Units (ICUs) on the study day.</p></div><div><h3>Main outcome measures</h3><p>Time awake overnight (22:00–06:00) was determined by structured nurse observation. The use of enterally administered sedative-hypnotic drugs prior to and during ICU admission was recorded, as was the use of a unit policy and non-pharmacological sleep promotion strategies.</p></div><div><h3>Results</h3><p>Data were available for 532 patients admitted to 40 ICUs (median age 60 years, 336 (63.2%) male, and 222 (41.7%) invasively ventilated). Forty-eight patients (9.0%) received an enteral pharmacological sleep aid, of which melatonin (28, 5.2%) was most frequently used. Patients not invasively ventilated were observed to be awake overnight for a median of 4.0 h (interquartile range (IQR): 2.5, 5.5), with no difference in those receiving an enteral hypnotic (p = 0.9). Non-pharmacological sleep aids were reportedly not offered or available for 52% (earplugs) and 63% of patients (eye masks). Only 7 (17.5%) participating ICUs had a policy informing sleep-optimising interventions.</p></div><div><h3>Conclusions</h3><p>Patients not receiving invasive ventilation appeared to spend many nocturnal hours awake. Pharmacological sleep aid administration was not associated with a greater observed time asleep. Most patients did not receive any non-pharmacological aid, and most ICUs did not have a local guideline or unit policy on sleep promotion.</p></div>","PeriodicalId":49215,"journal":{"name":"Critical Care and Resuscitation","volume":"26 3","pages":"Pages 192-197"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1441277224000255/pdfft?md5=57ab8f01891fcbe0c84f074506be7286&pid=1-s2.0-S1441277224000255-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142230348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Critical Care and Resuscitation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1